GREAT PARTNERSHIPS CREATE GREAT POSSIBILITIES

Bringing new acquisitions, licenses & partnerships into our portfolio



Future expansion in 3 core areas



Solid tumors & hematology

- Precision medicine approaches
- BIC/FIC with strong science and meaningful differentiation
- Smaller patient segments attractive for mid-sized companies



Rare Disease

High unmet needs in underserved rare diseases

Drive liver & bone franchises; expand to new disease areas

Good fit for clinical development & go-to-market model



Neuroscience



Expand havend neurotoxins in n

Expand beyond neurotoxins in non-rare to adjacent areas Strong innovation & scientific advances



No competing internal pipeline

Exclusively sourcing through external innovation

with a biotech mindset

Direct leadership
decision-making for
all programs
accelerates
execution



At Ipsen we believe in the power of partnerships to create great possibilities

We're seeking like-minded partners to join with us to deliver strong and successful outcomes





Together with Ipsen




FIPSEN

TOGETHER, LET'S MAKE A WORLD OF DIFFERENCE TO PATIENTS



Learn more about Ipsen: www.ipsen.com/partnering







Right-Size

With the proven ability to develop and bring your innovations to patients



Focuse

In 3 core areas: Oncology, Rare Disease, Neuroscience



Relationship Drive

Showing the same devotion to the success of your asset as you do

2027

Track record maximizing every asset worldwide across multiple indications

a global biopharma company...

Solid financial execution generating **€5bn** cumulative firepower by 20271



GROWING AND PUSHING BOUNDARIES

Global leader delivering >€3bn sales in 2023 with growth across all regions and therapeutic areas

- September 2024 YTD total sales growth 7% (at CER)
- 2027 Core Operating Margin ≥32% of total sales

Our teams in more than 40 countries and our partnerships around the world enable us to bring

partnerships around the world enable us to bring

medicines to patients in more than 80 countries.



Future growth:

One medicine:

sales ≥€500m

2020

Somatuline Autogel

FIPSEN

 $\Theta \Theta \Theta$

Europe of total

Future growth:

Four medicines:

sales ≥€500m

2023³

Dysport*

CABOMETYX*

Decapeptyl

of total

China, Asia-Pacific, Middle East & Latin America

Rest of World

Future growth:

Seven medicines: potential sales ≥€500m

> 2027+ Mike Burbridge Sr. Dir., External Innovation IQIR VO

Kalyan Chakravarthy

Assoc. Dir., External Innovation

Srimoyee Ghosh

Sr. Dir., External Innovation

Bylvay. (odevixibat)

onivyde®

Dysport[®] CABOMETYX*

Decapeptyl

TAZVERIK Somatuline Autogel

Rare Disease & Neuroscience **Global Partnering team**



Lori Badura VP, Head of Global Rare Disease Neuroscience Partnering



Late-Stage Global **Partnering Team**



Matthew Beard

Savitri Mandapati

Assoc. Dir., External Innovation

Sr. Dir., External Innovation

OUR GLOBAL PARTNERING & EXTERNAL INNOVATION TEAM

Global Partnering & External Innovation Management Team

Philippe Lopes-Fernandes

EVP. Chief Business Officer

Chris Hupp

Jon Travers

Sr. Dir., External Innovation

Sr. Dir., External Innovation

Guillaume Harmange

Principal Scientist, External Innovation

External Innovation Team

Anuradha Connor

VP, Head of Oncology

External Innovation

Jean-Patrick Hennebelle Sr. VP, Head of Global Late-Stage Partnering

David Jenkins

SVP, Head of Research

& External Innovation

Florence Dal Degan

Sr. Dir., External Innovation

Shira Landskroner-Eiger

Dir., External Innovation

Clément Gautier

Sr. Dir., Head of Neuroscience

& Rare Disease External Innovation



Romain Vitte Sr. Dir., Global Partnering

Jean-Baptiste de Peretti Sr. Mgr., Global Partnering

Oncology Global Partnering Team



Nick Gagnon VP, Head of Oncology Global Partnering



Jordan Gass Sr. Dir., Global Partnering



Madee Gooriah Sr. Dir., Global Partnering



Masha Kurbatova Sr. Dir., Global Partnering



Oncology

Rare Disease

Neuroscience

Aurore Bernier Gruson Dir., Global Partnering

Alliance Management Team



Naomi Binoche VP, Head of Alliance Management



Eric Ferrandis VP, Strategic Alliances



Dir., Strategic Alliances



Sarah Desi Sr. Dir., Strategic Alliances



Julie Marion

Sr. Dir, Strategic Alliances

Guillaume Gimonet Sr. Dir., Strategic Alliances







Benjamin Boiseau VP Global Partnering Strategy & Operations Head





Manager, Global **Partnering Operations**

² September YTD 2024 sales by region, ³ 2023 sales based on latest available consensus forecasts. Europe is defined in this presentation as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland.

Please contact the appropriate team member or email bus.devpt@ipsen.com

¹ Based on net debt at 2.0x EBITDA and excluding sale of any assets